CADTH Canadian Drug Expert Committee recommendation: Caplacizumab (Cablivi -- Sanofi-Aventis Canada Inc.) indication : for the treatment of adults with acquired thrombotic thrombocytopenic purpura
Caplacizumab is a humanized, bivalent nanobody targeting the A1 domain of von Willebrand factor to inhibit the interaction between von Willebrand factor and platelets. The Health Canada-approved indication is for the treatment of adults with aTTP in combination with plasma exchange and immunosuppres...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, September 1, 2020
|
| Edition: | Version: Final |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Caplacizumab is a humanized, bivalent nanobody targeting the A1 domain of von Willebrand factor to inhibit the interaction between von Willebrand factor and platelets. The Health Canada-approved indication is for the treatment of adults with aTTP in combination with plasma exchange and immunosuppressive therapy. Caplacizumab is available as powder for solution (11 mg per vial) for IV or subcutaneous (SC) injection |
|---|---|
| Physical Description: | 1 PDF file (8 pages) |